双期双能CT肺动脉造影评估肺高压的血管与实质强化
前瞻性纳入102例同时行右心导管和双期双能CT肺动脉造影的连续受试者,评估强化定量与平均肺动脉压及肺血管阻力的相关性。双期双能CT的灌注血容量变化定义肺高压的AUC最高(mPAP 0.78,PVR 0.79),联合主肺动脉大小和右左心室比值相关性最高(mPAP r=0.71,PVR r=0.64)。双期双能CT强化定量似乎可改善无创肺高压评估中对mPAP和PVR的预测。
要点
- 双期双能CT的灌注血容量变化(WLenh变化)对mPAP和PVR定义的肺高压诊断AUC分别为0.78和0.79。
- 系列1中肺高压者PAenh/WLenh比值更高、WLenh和DAenh更低;系列2中PAenh和WLenh更高。
- 联合双能CT指标、主肺动脉大小和右左心室比值与mPAP(r=0.71)和PVR(r=0.64)相关性最高。
核心结论
- 双期双能CT肺动脉造影强化定量似乎可改善无创肺高压评估中对mPAP和PVR的预测。
研究设计与样本
- 前瞻性研究,2012至2014年连续纳入同时行右心导管和双期双能CT肺动脉造影的受试者102例(中位年龄70岁,范围58-78岁,60例女性)。
- CT评估包括标准肺动脉期双能CT肺动脉造影采集(系列1),系列1完成后7秒行第二次双能CT肺动脉造影采集,限于肺血管中心10 cm(系列2)。
- 从双能CT肺动脉造影碘图中计算主肺动脉强化(PAenh)、降主动脉强化(DAenh)和全肺灌注血容量(WLenh)。
- 以右心导管测定的平均肺动脉压(mPAP)和肺血管阻力(PVR)为参考标准。
关键影像表现/征象
- 系列1中,肺高压者(无论按mPAP≥25 mm Hg还是PVR>3 Wood units定义)PAenh/WLenh比值更高,WLenh和DAenh更低(P < .05)。
- 系列2中,肺高压者PAenh和WLenh更高(P < .05)。
诊断标准与关键数值
- WLenh变化定义mPAP疾病的AUC为0.78,定义PVR疾病的AUC为0.79,与mPAP相关性r=0.62。
- 系列2 PAenh与PVR相关性r=0.49。
- 多线性回归纳入WLenh和系列1 DAenh后PVR相关性r=0.56。
- 联合双能CT指标、主肺动脉大小和右左心室比值与mPAP相关性r=0.71,与PVR相关性r=0.64。
临床应用与阅片要点
- 双期双能CT肺动脉造影的强化定量(尤其WLenh变化)可能有助于无创评估肺高压,但原文为「似乎」改善预测,需结合临床。
- 系列1中PAenh/WLenh比值升高及WLenh、DAenh降低,系列2中PAenh和WLenh升高,可能提示肺高压,阅片时可关注这些定量指标。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate pulmonary hypertension (PH) determination by dual-phase dual-energy CT pulmonary angiography vascular enhancement and perfused blood volume (PBV) quantification.
MATERIALS AND METHODS: In this prospective study, consecutive participants who underwent both right heart catheterization and dual-phase dual-energy CT pulmonary angiography were included between 2012 and 2014. CT evaluation comprised a standard pulmonary arterial phase dual-energy CT pulmonary angiography acquisition (termed series 1) followed 7 seconds after series 1 completion by a second dual-energy CT pulmonary angiography acquisition limited to the central 10 cm of the pulmonary vasculature (termed series 2). In both series, enhancement in the main pulmonary artery (PAenh), the descending aorta (DAenh), and whole-lung PBV (WLenh) was calculated from dual-energy CT pulmonary angiography iodine images. Dual-energy CT pulmonary angiography and standard cardiovascular metrics were correlated to mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR) with additional receiver operating characteristic curve analysis.
RESULTS: A total of 102 participants (median age, 70; range, 58-78 years; 60 women) were included. Sixty-five participants had PH defined by mPAP of greater than or equal to 25 mm Hg, and 51 participants had PH defined by PVR of greater than 3 Wood units. By either definition, participants with PH had higher PAenh/WLenh ratio and lower WLenh and DAenh in series 1 (P < .05) and higher PAenh and WLenh in series 2 (P < .05). Change in WLenh determined highest diagnostic accuracy to define disease by mPAP (area under the receiver operating characteristic curve [AUC], 0.78) and PVR (AUC, 0.79) and the best mPAP correlation (r = 0.62). PAenh series 2 correlated best with PVR (r = 0.49). Multiple linear regression analysis incorporating WLenh and series 1 DAenh improved PVR correlation (r = 0.56). Combining these dual-energy CT pulmonary angiography metrics with main pulmonary artery size and right-to-left ventricular ratio achieved the highest correlations (mPAP, r = 0.71; PVR, r = 0.64).
CONCLUSION: Dual-phase dual-energy CT pulmonary angiography enhancement quantification appears to improve mPAP and PVR prediction in noninvasive PH evaluation.Supplemental material is available for this article.See also the commentary by Kay in this issue.© RSNA, 2020.
引用
- Bacon JL, Madden BP, Gissane C, et al. Vascular and Parenchymal Enhancement Assessment by Dual-Phase Dual-Energy CT in the Diagnostic Investigation of Pulmonary Hypertension. Radiol Cardiothorac Imaging. 2020. PMID: 33778636. doi:10.1148/ryct.2020200009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。